RTA 408 (omaveloxolone)  Friedreich’s Ataxia News

RTA 408 (omaveloxolone) is an oral, small molecule Nrf2 activator to treat Friedrich’s ataxia now being evaluated in an ongoing Phase 2 clinical trial.

X